Christophe Piketty
机构：Galderma (Switzerland) · ORCID：0000-0002-9969-2478
发表论文 172 篇 · 总被引 5864 次 · h-index 39
代表论文
- Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis (2024 · JAMA Dermatology · 被引 59)
- Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study (2025 · Journal of the European Academy of Dermatology and Venereology · 被引 7)
- Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis (2025 · Journal of the European Academy of Dermatology and Venereology · 被引 6)
- Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies (2025 · Journal of the European Academy of Dermatology and Venereology · 被引 6)
- Patients’ Experiences of Atopic Dermatitis and Nemolizumab Treatment: An In-Trial Interview Study Embedded in a Phase 3 Clinical Trial (ARCADIA) (2025 · Patient · 被引 2)
- Epidemiology of prurigo nodularis: An analysis of global trends from 1998 to 2023 (2025 · Clinical Epidemiology and Global Health · 被引 2)